Compare
NAVs as of 20 Aug 2026
Add a second fund to compare. Until then every figure below is shown against the Index Funds median (375 funds), which is the only comparison one fund can support.
Growth of ₹100 (rebased over the selected window)
Common period 28 Nov 2022 – 20 Aug 2026, limited by HSBC NIFTY 50 Index Fund. Every series is rebased to ₹100 at the start of this window. Benchmark lines are the category index WealthTicker measures against, which is not always the benchmark the scheme itself declares — the fund page’s Scheme Info names that one.
View as table
| Date | HSBC NIFTY 50 Index Fund | Nifty 50 |
|---|---|---|
| 28 Nov 2022 | ₹100.00 | ₹100.00 |
| 21 Mar 2023 | ₹92.09 | ₹92.16 |
| 13 Jul 2023 | ₹104.98 | ₹104.58 |
| 03 Nov 2023 | ₹104.42 | ₹103.60 |
| 25 Feb 2024 | ₹120.75 | ₹119.66 |
| 17 Jun 2024 | ₹128.06 | ₹126.41 |
| 09 Oct 2024 | ₹136.67 | ₹134.58 |
| 30 Jan 2025 | ₹127.44 | ₹125.25 |
| 23 May 2025 | ₹136.38 | ₹133.89 |
| 14 Sep 2025 | ₹138.80 | ₹135.29 |
| 05 Jan 2026 | ₹145.23 | ₹141.41 |
| 29 Apr 2026 | ₹133.88 | ₹130.25 |
| 20 Aug 2026 | ₹135.09 | ₹130.54 |
| Metric | HSBC · Direct NAV ₹28.70 Very High risk ★★★☆☆ | Category median Index Funds · 375 funds |
|---|---|---|
| -2.41% | +5.66% | |
| +8.89% | +8.82% | |
| — | +9.15% | |
| — | +11.72% | |
| +8.41% | +7.67% | |
| +5.78% | — | |
| +11.17% | +12.67% | |
| — | +13.64% | |
| — | +12.84% | |
| Risk | ||
| 13.21% | 13.97% | |
| 0.18 | 0.24 | |
| 0.25 | 0.36 | |
| -15.51% | -16.12% | |
| Nifty 50 | — | |
| +0.93% | +0.84% | |
| 1.00 | 1.00 | |
| 102.2% | 102.2% | |
| 96.7% | 97.2% | |
| 0.22% | 0.36% | |
| ₹376.89Cr | ₹177.09Cr | |
| Up to 1.00% | — | |
| None | — | |
| ₹500 | — | |
| ₹5.00K | — | |
| 14% | 35% | |
| Praveen Ayathan | — | |
| 28 Nov 2022 | — | |
| 50 | — | |
| 53.5% | — | |
| 0.2% | — | |
Best marks the strongest value in a row, and only where the gap is bigger than noise — a near-tie is left unmarked rather than dressed up as a result. SIP XIRR is a ₹10,000/month instalment over 5 years of real NAV history. Nothing here is supplied by a fund house. For research only — not investment advice.